Original Article

You have full text access to this OnlineOpen article

Do adjuvant aromatase inhibitors increase the cardiovascular risk in postmenopausal women with early breast cancer†

Meta-analysis of randomized trials

  1. Federica Cuppone MD1,‡,
  2. Emilio Bria MD1,‡,§,*,
  3. Sunil Verma MD2,
  4. Kathleen I. Pritchard MD2,¶,
  5. Sonal Gandhi MD2,
  6. Paolo Carlini MD1,
  7. Michele Milella MD1,
  8. Cecilia Nisticò MD1,
  9. Edmondo Terzoli MD1,
  10. Francesco Cognetti MD1,
  11. Diana Giannarelli MS3

Article first published online: 26 NOV 2007

DOI: 10.1002/cncr.23171

Issue

Cancer

Cancer

Volume 112, Issue 2, pages 260–267, 15 January 2008

Additional Information

How to Cite

Cuppone, F., Bria, E., Verma, S., Pritchard, K. I., Gandhi, S., Carlini, P., Milella, M., Nisticò, C., Terzoli, E., Cognetti, F. and Giannarelli, D. (2008), Do adjuvant aromatase inhibitors increase the cardiovascular risk in postmenopausal women with early breast cancer. Cancer, 112: 260–267. doi: 10.1002/cncr.23171

Author Information

  1. 1

    Department of Medical Oncology, Regina Elena National Cancer Institute, Rome, Italy

  2. 2

    Division of Medical Oncology, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada

  3. 3

    Department of Biostatistics, Regina Elena National Cancer Institute, Rome, Italy

  1. ‡

    The first two authors contributed equally to this article.

  2. §

    Fax: (011) 390652666219

  3. Dr. Pritchard has acted as a consultant with Sanofi-Aventis, AstraZeneca, Roche, Pfizer, Ortho-Biotech, YM Biosciences, Biomira, and Novartis. She has received research funding either directly through per case funding for studies or indirectly through the National Cancer Institute of Canada Clinical Trials Group, contracted with pharmaceutical companies from AstraZeneca, YM Biosciences, Bristol-Myers-Squibb, Sanofi-Aventis, Amgen, Ortho-Biotech, Pfizer, and Novartis. She also has received honoraria from Sanofi-Aventis, AstraZeneca, Pfizer, Roche, Aegera, YM Biosciences, and Novartis and has given paid testimony for Sanofi-Aventis and AstraZeneca. She has been a member of an Advisory Committee for Sanofi-Aventis, AstraZeneca, Ortho-Biotech, Roche, Pfizer, Novartis, Aegera, and YM Biosciences

*Department of Medical Oncology, Regina Elena National Cancer Institute, Via Elio Chianesi 53, 00144, Rome, Italy

  1. †

    Presented at the Annual Meeting of the European Society for Medical Oncology, Istanbul, Turkey, September 29–October 3, 2006.

Publication History

  1. Issue published online: 4 JAN 2008
  2. Article first published online: 26 NOV 2007
  3. Manuscript Accepted: 16 AUG 2007
  4. Manuscript Revised: 10 AUG 2007
  5. Manuscript Received: 11 JUL 2007

Funded by

  • Paola Muti, MD
  • Scientiphic Director, ‘Regina Elena’ National Cancer Institute, Rome, Italy

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (203K)

REFERENCES

  • 1
    Jemal A,Siegel R,Ward E, et al. Cancer statistics, 2006. CA Cancer J Clin. 2006; 56: 106–130.
    Direct Link:
  • 2
    Bria E,Carlini P,Cognetti F,Terzoli E,Giannarelli D. Re: survival with aromatase inhibitors and inactivators versus standard hormonal therapy in advanced breast cancer: meta-analysis [letter]. J Natl Cancer Inst. 2007; 99: 176; author reply 176–177.
  • 3
    Carlini P,Bria E,Ferretti G, et al. New aromatase inhibitors (AIs) as first-line endocrine therapy (ET) in metastatic breast cancer (MBC): a pooled analysis of 3238 women from 8 phase III trials. J Clin Oncol. (Meeting Abstracts). 2005; 23( 16S). Abstract 602.
  • 4
    Mauri D,Pavlidis N,Polyzos NP,Ioannidis JP. Survival with aromatase inhibitors and inactivators versus standard hormonal therapy in advanced breast cancer: meta-analysis. J Natl Cancer Inst. 2006; 98: 1285–1291.
  • 5
    Boccardo F,Rubagotti A,Guglielmini P, et al. Switching to anastrozole versus continued tamoxifen treatment of early breast cancer. Updated results of the Italian Tamoxifen Anastrozole (ITA) trial. Ann Oncol. 2006; 17( suppl 7): vii10–vii14.
  • 6
    Boccardo F,Rubagotti A,Puntoni M, et al. Switching to anastrozole versus continued tamoxifen treatment of early breast cancer: preliminary results of the Italian Tamoxifen Anastrozole Trial. J Clin Oncol. 2005; 23: 5138–5147.
  • 7
    Bria E,Ciccarese M,Giannarelli D, et al. Early switch with aromatase inhibitors as adjuvant hormonal therapy for postmenopausal breast cancer: pooled-analysis of 8794 patients. Cancer Treat Rev. 2006; 32: 325–332.
  • 8
    Buzdar A,Howell A,Cuzick J, et al. Comprehensive side-effect profile of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: long-term safety analysis of the ATAC trial. Lancet Oncol. 2006; 7: 633–643.
  • 9
    Coates AS,Keshaviah A,Thurlimann B, et al. Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of Study BIG 1–98. J Clin Oncol. 2007; 25: 486–492.
  • 10
    Coombes RC,Hall E,Gibson LJ, et al. A randomized trial of exemestane after 2 to 3 years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med. 2004; 350: 1081–1092.
  • 11
    Coombes RC,Paridaens R,Jassem J, et al. First mature analysis of the Intergroup Exemestane Study. J Clin Oncol (Meeting Abstracts). 2006; 24. Abstract LBA527.
  • 12
    Howell A,Cuzick J,Baum M, et al. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer. Lancet. 2005; 365: 60–62.
  • 13
    Jakesz R,Jonat W,Gnant M, et al. Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years' adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trial. Lancet. 2005; 366: 455–462.
  • 14
    Jonat W,Gnant M,Boccardo F, et al. Effectiveness of switching from adjuvant tamoxifen to anastrozole in postmenopausal women with hormone-sensitive early-stage breast cancer: a meta-analysis. Lancet Oncol. 2006; 7: 991–996.
  • 15
    Thurlimann B,Keshaviah A,Coates AS, et al. A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. N Engl J Med. 2005; 353: 2747–2757.
  • 16
    Nabholtz JM,Gligorov J. Cardiovascular safety profiles of aromatase inhibitors: a comparative review. Drug Saf. 2006; 29: 785–801.
  • 17
    Pritchard KI,Abramson BL. Cardiovascular health and aromatase inhibitors. Drugs. 2006; 66: 1727–1740.
  • 18
    Gandhi S,Verma S. Aromatase inhibitors and cardiac toxicity: getting to the heart of the matter. Breast Cancer Res Treat. 2007; 1006: 1–9.
  • 19
    Goss PE,Ingle JN,Martino S, et al. Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17. J Natl Cancer Inst. 2005; 97: 1262–1271.
  • 20
    Pignon JP,Hill C. Meta-analyses of randomised clinical trials in oncology. Lancet Oncol. 2001; 2: 475–482.
  • 21
    Case LD,Kimmick G,Paskett ED,Lohman K,Tucker R. Interpreting measures of treatment effect in cancer clinical trials. Oncologist. 2002; 7: 181–187.
  • 22
    Bria E,Nistico C,Cuppone F, et al. Benefit of taxanes as adjuvant chemotherapy for early breast cancer: pooled analysis of 15,500 patients. Cancer. 2006; 106: 2337–2344.
    Direct Link:
  • 23
    Parmar M,Machin D. Survival Analysis: A Practical Approach. Chichester, United Kingdom: John Wiley & Sons; 1995.
  • 24
    Altman DG. Confidence intervals for the number needed to treat. BMJ. 1998; 317: 1309–1312.
  • 25
    Boccardo F,Rubagotti A,Amoroso D, et al. Sequential tamoxifen and aminoglutethimide versus tamoxifen alone in the adjuvant treatment of postmenopausal breast cancer patients: results of an Italian cooperative study. J Clin Oncol. 2001; 19: 4209–4215.
  • 26
    Coombes RC,Kilburn LS,Snowdon CF, et al. Survival and safety of exemestane versus tamoxifen after 2–3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial. Lancet. 2007; 369: 559–570.
  • 27
    Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet. 2005; 365: 1687–1717.
  • 28
    Del Mastro L,Venturini M. ATAC trial update [letter]. Lancet. 2005; 365: 1225; author reply 1225–1226.
  • 29
    Montori VM,Devereaux PJ,Adhikari NK, et al. Randomized trials stopped early for benefit: a systematic review. JAMA. 2005; 294: 2203–2209.
  • 30
    Braithwaite RS,Chlebowski RT,Lau J,George S,Hess R,Col NF. Meta-analysis of vascular and neoplastic events associated with tamoxifen. J Gen Intern Med. 2003; 18: 937–947.
    Direct Link:
  • 31
    Brufsky A,Harker WG,Beck JT, et al. Zoledronic acid inhibits adjuvant letrozole-induced bone loss in postmenopausal women with early breast cancer. J Clin Oncol. 2007; 25: 829–836.
  • 32
    Gnant MF,Mlineritsch B,Luschin-Ebengreuth G, et al. Zoledronic acid effectively prevents cancer treatment-induced bone loss in premenopausal women receiving adjuvant endocrine therapy for hormone-responsive breast cancer: a report from the Austrian Breast and Colorectal Cancer Study Group. J Clin Oncol. 2007; 25: 820–828.
  • 33
    Egger M,Smith GD,Altman DG. Systematic Reviews in Health Care: Meta-analysis in Context. London, United Kingdom: BMJ Publication Group; 2001.
  • 34
    Piedbois P,Buyse M. Meta-analyses based on abstracted data: a step in the right direction, but only a first step. J Clin Oncol. 2004; 22: 3839–3841.
  • 35
    Bria E,Ruggeri EM,Pollera CF,Terzoli E,Cognetti F,Giannarelli D. Adjuvant chemotherapy for bladder cancer: the chance for meta-analyses comparison. Eur Urol. 2007; 51: 576–577.
View Full Article (HTML) Get PDF (203K)